Cardiol Therapeutics Inc Class A saw a notable increase in its stock price during yesterday's trading session.
Shares of Cardiol Therapeutics Inc Class A (CRDL.TO) climbed 6.98% to close at CA$2.76. This rise reflects positive market sentiment surrounding the company, even without any major news announcements.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$301.40M
52W high
$2.79
52W low
$1.23
1W change
+5.75%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 117.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+117.4% Upside
Current Price
C$2.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
70.2%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.30
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.93 | C$2.30 โ C$3.73 |
| 60 trading days | C$3.11 | C$2.21 โ C$4.38 |
| 90 trading days | C$3.30 | C$2.17 โ C$5.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the potential for growth in Cardiol Therapeutics, especially given its ongoing clinical developments and market interest.
Cardiol Therapeutics Inc Class A's stock rose by 6.98% yesterday.
With a market cap of CA$301.4 million, Cardiol's recent performance could attract further attention from investors looking for growth opportunities in the biotech sector.
Bull case
The rise in stock price may show increasing investor confidence in Cardiol's pipeline, particularly after the release of its Phase II data on recurrent pericarditis. This data could strengthen its position in the market.
Bear case
Despite the recent gains, investors should stay cautious. The lack of significant news could lead to volatility, and the companyโs profitability remains uncertain.
Market Reaction and Performance
Advertisement
The stock of Cardiol Therapeutics Inc Class A experienced a strong increase during yesterday's trading session, closing at CA$2.76. This performance is notable, especially since there were no major announcements to explain such a surge. Investors might see this as a sign of underlying confidence in the company's future.
Potential Drivers Behind the Surge
While no specific news triggered the rise, the recent publication of Cardiol's Phase II study results on recurrent pericarditis likely boosted investor sentiment. As the company continues its important clinical trials, market watchers will be eager to see how these developments affect its growth trajectory.
Looking Ahead
As Cardiol Therapeutics Inc Class A moves forward, investors should keep an eye on upcoming announcements and clinical trial results. The stock's recent performance could signal further gains, but the inherent risks in biotech investments call for a cautious approach.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
